ENARA BIO LIMITED

Active Oxford

Research and experimental development on biotechnology

58 employees website.com
Life sciences and medical technology Research and experimental development on biotechnology
E

ENARA BIO LIMITED

Research and experimental development on biotechnology

Founded 8 Nov 2016 Active Oxford, United Kingdom 58 employees website.com
Life sciences and medical technology Research and experimental development on biotechnology

Previous Company Names

ERVAXX LIMITED 8 Nov 2016 — 3 Jun 2020
Accounts Submitted 28 Aug 2025 Next due 30 Sept 2026 5 months remaining
Confirmation Submitted 10 Nov 2025 Next due 21 Nov 2026 7 months remaining
Net assets £13M £3M 2024 year on year
Total assets £16M £433K 2024 year on year
Total Liabilities £3M £3M 2024 year on year
Charges 1
1 satisfied

Contact & Details

Contact

Registered Address

Magdalen Centre The Oxford Science Park 1 Robert Robinson Avenue Oxford Oxfordshire OX4 4GA United Kingdom

Telephone

0800 000 0000

Email

info@example.com

Website

www.example.com

Full company profile for ENARA BIO LIMITED (10469748), an active life sciences and medical technology company based in Oxford, United Kingdom. Incorporated 8 Nov 2016. Research and experimental development on biotechnology. View financials, directors, shareholders, and filings.

Business Summary

This company specializes in providing innovative solutions and services across multiple sectors.

Products & Services

consulting software analytics integration

Reports

Credit Report

In-depth credit score, financial analysis, risk assessment and company intelligence.

Financials

Financials

Period 1 Jan → 31 Dec 2024
Type Total Exemption Full
Next accounts 31 December 2025
Due by 30 September 2026 9 months

Net Assets, Total Assets & Total Liabilities (2023–2024)

Cash in Bank

£9.44M

Decreased by £2.42M (-20%)

Net Assets

£13.35M

Increased by £3.12M (+30%)

Total Liabilities

£2.58M

Decreased by £2.68M (-51%)

Turnover

£2.57M

Decreased by £14.85M (-85%)

Employees

58

Increased by 4 (+7%)

Debt Ratio

16%

Decreased by 18 (-53%)

Financial History

Revenue, profit, EBITDA and key financial figures

2024
Dec Year End
2023
Dec Year End
P&L
Revenue
£142.3M
£128.7M
Gross Profit
£48.2M
£43.1M
Operating Profit
£22.4M
£19.8M
Net Profit
£18.1M
£15.9M
EBITDA
£31.5M
£28.2M
Assets
Cash
£24.7M
£21.3M
Total Assets
£89.4M
£82.1M
Liabilities
Total Liabilities
£45.2M
£41.8M
Key Metrics
Employees
1,247
1,156
Latest Revenue
£142.3M
Latest EBITDA
£31.5M
Cash Position
£24.7M

Funding

Fundraising & Grants

Funding Rounds 4

Investors (7)

Investor NameInvestor SinceParticipating Rounds
Investor 1Nov 2019Series A, Series B
Investor 2Nov 2019Series A
Investor 3Nov 2019Series A, Series B

Share Capital

Share Capital

Share allotments and capital structure

61 Allotments 118,143,327 Shares £37.68m Total
Date FromShare ClassShares AllottedAmount RaisedPrice/Share
26 Feb 202672,446£1k£0.018
26 Feb 2026193,532£4k£0.019
26 Feb 202623,216£2.322£0
30 Oct 202560,067£1k£0.018
30 Oct 202528,989£539.195£0.019

Officers

Officers

2 active 1 resigned
Status
Bauke AnningaDirectorDutchNetherlands3929 Aug 2024Active
Rana Abdul Raouf Al-hallaqDirectorAmericanUnited States5029 Aug 2024Active

Shareholders

Shareholders (67)

Pfizer Ventures (us) Llc
19.5%
20,957,770
Merck Ventures B.v
14.6%
15,718,327

Persons with Significant Control

Persons with Significant Control (0)

0 Active 3 Ceased

Rajeev Shah

Ceased 30 Aug 2024

Ceased

Peter Kolchinsky

Ceased 30 Aug 2024

Ceased

Professor Houman Ashrafian

Ceased 18 Dec 2017

Ceased

Group Structure

Group Structure

No group structure identified

Charges

Charges

1 satisfied

Properties

Properties

0 total

No related properties

Documents

Company Filings

DateCategoryDescriptionDocument
12 Mar 2026CapitalAllotment of shares (GBP 10,777.3463) on 2026-03-02
3 Mar 2026ResolutionResolutions
3 Mar 2026IncorporationMemorandum Articles
10 Nov 2025Confirmation StatementConfirmation statement made on 2025-11-07 with updates
6 Nov 2025OfficersChange to director Mr Kevin Robert Pojasek on 2024-12-01
12 Mar 2026 Capital

Allotment of shares (GBP 10,777.3463) on 2026-03-02

3 Mar 2026 Resolution

Resolutions

3 Mar 2026 Incorporation

Memorandum Articles

10 Nov 2025 Confirmation Statement

Confirmation statement made on 2025-11-07 with updates

6 Nov 2025 Officers

Change to director Mr Kevin Robert Pojasek on 2024-12-01

Recent Activity

Latest Activity

Allotment of shares (GBP 10,777.3463) on 2026-03-02

1 months ago on 12 Mar 2026

Resolutions

1 months ago on 3 Mar 2026

Memorandum Articles

1 months ago on 3 Mar 2026

Confirmation statement made on 2025-11-07 with updates

5 months ago on 10 Nov 2025

Change to director Mr Kevin Robert Pojasek on 2024-12-01

5 months ago on 6 Nov 2025